Combinatory Therapy Antimicrobial Peptide-Antibiotic to Minimize the Ongoing Rise of Resistance

Pizzolato-Cezar, Luis R; Okuda-Shinagawa, Nancy M.; Miranda, Maria Terêsa Machini de

doi:10.3389/fmicb.2019.01703

Cited by 64 publications

(53 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is when even simple infectious diseases are not treatable due to a significant increase in the resistance of pathogens to antibacterial preparations (WHO, 2017;MOZ, 2018). The severity of the problem of the development of antibiotic resistance prompts doctors and scientists around the world to seek alternative treatments for infectious diseases (Chaudhary, 2016;Richardson et al, 2017;WHO, 2017;Pizzolato-Cezar et al, 2019) and to guide developments to reduce the likelihood of developing antibiotic resistance and reduce the number of resistant strains of microorganisms (WHO, 2018;Pizzolato-Cezar et al, 2019). It has been found that the effect of antibacterial preparations correlates with the formation of resistance in pathogens (Pizzolato-Cezar et al, 2019).…”

Section: Discussionmentioning

confidence: 99%

“…Studies by many authors have proved the effectiveness of the use of antimicrobial substances LL-37, bufferin II, ceprocine P1, machinin II with antibacterial drugs -polymyxin, piperacillin, azithromycin, daptomycin, linezolid, clarithromycin. Combined use is accompanied by an increase in the therapeutic effect of antibiotics against gram-negative, grampositive microorganisms, as well as against pathogens with high multiple drug resistance (Pizzolato-Cezar et al, 2019). The potentiation of rifampin, meropenem, aztreonam, tobramycin was due to SET-M33 against the multiresistant strains of Klebsiella pneumoniae, Acinetobacter baumannii, and ciprofloxacin was also noted against P. aeruginosa (Pollini et al, 2017).…”

Section: Introductionmentioning

confidence: 99%

“…As of today it is relevant to implement alternative methods of treatment of infections caused by different microorganisms and to develop combined approaches for the treatment of infectious diseases (Lewies et al, 2018;Xu et al, 2018;Pizzolato-Cezar et al, 2019). Biologically active substances of probiotic origin, as alternative methods for the treatment of infectious diseases, are taking leading positions.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Synergistic activity of filtrates of Lactobacillus rhamnosus and Saccharomyces boulardii and antibacterial preparations against Corynebacterium spp.

Isayenko

2019

Regul. Mech. Biosyst.

View full text Add to dashboard Cite

We present the results of the first study of the combined influence of the biologically active substances Lactobacillus rhamnosus GG ATCC 53103 and Saccharomyces boulardii, obtained by the author’s method, and antibacterial agents on Corynebacterium spp. The first area of research was the study of increasing the sensitivity of toxigenic microorganisms to antimicrobial drugs due to the consecutive effects of the structural components and metabolites of L. rhamnosus GG and S. boulardii and antibacterial drugs on Corynebacterium spp. tox+. The greatest increase in the sensitivity of test-cultures of corynebacteria to penicillin (by 19.4 mm), imipenem (by 15.0 mm), vancomycin (by 12.0 mm), gentamicin (by 11.0 mm), ciprofloxacin (by 9.8 mm), erythromycin (by 9.6 mm), cefotaxime (by 9.5 mm) occurred due to the products of lactobacteria and a combination of metabolites of lactobacteria and saccharomycetes. The second area of research was the study of the synergic activity of substances L. rhamnosus GG and S. boulardii and traditional antibacterial drugs manifested by their simultaneous effect on Corynebacterium spp. Maximum potentiation of azithromycin (by 4.6 mm), erythromycin (by 4.5 mm), cefotaxime (by 2.2 mm), ceftriaxone (by 1.6 mm) and ampicillin (by 1.0 mm) relative to corynebacteria was also observed under the influence of lactobacteria metabolites and a combination of lactobacteria and saccharomycetes metabolites. Different degrees of manifestation of the combined action of biologically active substances L. rhamnosus GG and S. boulardii with antibiotics were determined, which depended on the selected combinations, the method of influence on the microorganism, the individual sensitivity of the test-cultures, the activity of the test filtrates and the initial concentration of the producers used to obtain the products of vital activity of lactobacteria and saccharomyces. The presented complexes of structural components and metabolites of L. rhamnosus GG and S. boulardii, obtained without the use of traditional nutrient media, by increasing the bioavailability of pathogenic pathogens can reduce the required concentration of the antibiotic, continuing their use, and suspend the likelihood of pathogens developing resistance to microorganisms. This makes them promising candidates both for the development of "accompaniment-preparations" for antibiotics for the additional therapy of infectious diseases of different etiology, and for the creation of a new direction of antimicrobial agents with multifunctional capabilities. Synergistic activity of filtrates L. rhamnosus GG and S. boulardii and antibacterial preparations against Corynebacterium spp.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Synergistic activity of filtrates of Lactobacillus rhamnosus and Saccharomyces boulardii and antibacterial preparations against Corynebacterium spp.

Isayenko

2019

Regul. Mech. Biosyst.

View full text Add to dashboard Cite

show abstract

“…For example, combination therapy with the antimicrobial peptide DP7 eradicated vancomycin and azithromycin resistance in Staphylococcus aureus, Pseudomonas aeruginosa , and Escherichia coli [ 57 ]. Additionally, in vitro synergy has been observed between many antimicrobial peptides and antibiotics [ 58 , 59 , 60 ]. This demonstrates particular clinical relevance where the toxicity or adverse side effects of a drug may be reduced when used in combination, at lower dosages.…”

Section: Therapeutic Potential Of Antimicrobial Peptidesmentioning

confidence: 99%

A New Era of Antibiotics: The Clinical Potential of Antimicrobial Peptides

Browne

Chakraborty

Chen

et al. 2020

IJMS

322

241

View full text Add to dashboard Cite

Antimicrobial resistance is a multifaceted crisis, imposing a serious threat to global health. The traditional antibiotic pipeline has been exhausted, prompting research into alternate antimicrobial strategies. Inspired by nature, antimicrobial peptides are rapidly gaining attention for their clinical potential as they present distinct advantages over traditional antibiotics. Antimicrobial peptides are found in all forms of life and demonstrate a pivotal role in the innate immune system. Many antimicrobial peptides are evolutionarily conserved, with limited propensity for resistance. Additionally, chemical modifications to the peptide backbone can be used to improve biological activity and stability and reduce toxicity. This review details the therapeutic potential of peptide-based antimicrobials, as well as the challenges needed to overcome in order for clinical translation. We explore the proposed mechanisms of activity, design of synthetic biomimics, and how this novel class of antimicrobial compound may address the need for effective antibiotics. Finally, we discuss commercially available peptide-based antimicrobials and antimicrobial peptides in clinical trials.

show abstract

“…The development of antibiotics since the 1940s proved important in eradicating bacteria, thereby saving millions of patients' lives. However, the conventional antibiotics used for anti-bacterial therapy exhibit some limitations in modern medicine, including the low bioavailability, minimal permeation to the infection nidus, and the rise of drug-resistant bacteria (superbugs) (Pizzolato-Cezar et al, 2019). The abuse and misuse of antibiotics has led to the emergence of antibiotic-resistant bacteria threatening human health.…”

Section: Introductionmentioning

confidence: 99%

Nano-Based Drug Delivery or Targeting to Eradicate Bacteria for Infection Mitigation: A Review of Recent Advances

et al. 2020

View full text Add to dashboard Cite

Combinatory Therapy Antimicrobial Peptide-Antibiotic to Minimize the Ongoing Rise of Resistance

Cited by 64 publications

References 41 publications

Synergistic activity of filtrates of Lactobacillus rhamnosus and Saccharomyces boulardii and antibacterial preparations against Corynebacterium spp.

Synergistic activity of filtrates of Lactobacillus rhamnosus and Saccharomyces boulardii and antibacterial preparations against Corynebacterium spp.

A New Era of Antibiotics: The Clinical Potential of Antimicrobial Peptides

Nano-Based Drug Delivery or Targeting to Eradicate Bacteria for Infection Mitigation: A Review of Recent Advances

Contact Info

Product

Resources

About